Navigation Links
Amarantus Completes Name Change and CUSIP Change
Date:12/3/2012

SUNNYVALE, Calif., Dec. 3, 2012 /PRNewswire/ -- Amarantus Bioscience, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has completed a name change from Amarantus Biosciences, Inc. to Amarantus Bioscience, Inc. In conjunction with this announcement, the Company has received a new Committee on Uniform Securities Identification Procedures (CUSIP) number of 02300T109. The Company's International Securities Identification Number has also changed to US02300T1097. These changes are part of an ongoing effort to improve the regularity of trading in the Company's common stock. These changes will have no impact on the marketability of the Company's securities, or the ability to trade the common stock through brokerage firms.

The Company believes that its fundamentals remain strong and is looking forward to continuing to update the marketplace regarding developments on an ongoing basis. The Company has not entered into any financing transactions that would cause shareholder dilution since the Company's 10Q was reported on November 19th, 2012. The Company has not sold any shares into the marketplace. None of the officers or directors of the Company have sold any shares into the marketplace. The officers and directors of the corporation continue to believe in the Company and its fundamentals.

About Amarantus Bioscience, Inc.

Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-d
'/>"/>

SOURCE Amarantus Bioscience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
2. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
3. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
6. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
7. Amarantus BioSciences Secures $1.1 Million in Financing
8. Amarantus BioSciences Issues CEO Letter to Shareholders
9. Amarantus BioSciences Wins MANF Patent Challenge in Europe
10. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
11. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... new study published today in the journal PNAS ... found that time of day and sleep deprivation have ... be crucial when looking at the best time of ... heart disease, and for administering medicines effectively. , Researchers ... Cancer Research, London, investigated the links between sleep deprivation, ...
(Date:7/10/2014)... out for crude 3-D glasses, polarized glasses, and ... basic devices, used to trick the brain into ... rendered obsolete with the introduction of new holography ... TAU doctoral students Yuval Yifat, Michal Eitan, and ... on nanoantennas that could be used for security ...
(Date:1/15/2014)...  Bill Jacobs Automotive, a group of car dealerships headquartered in ... Heartland Blood Center and offering free oil change coupons for ... Saturday, Jan. 18 at the Bill Jacobs Cadillac and Chevrolet ... http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs Auto ...
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
Breaking Biology Technology:Time of day crucial to accurately test for diseases, new research finds 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3Join the Bill Jacobs Auto blood drive and receive a free oil change 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3
... Purpose , ... of protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) ... of assessing inter-individual and intra-individual metabolism variability. To be of ... to monitor these drugs is fast and easy to perform, ...
... Introduction , ... products are radioactively labeled using either endlabeled primers or ... Successful sequencing results produced by these two labeling methods ... breaks, impurities or high secondary structure can cause DNA ...
... , Researchers and forensic agencies that test samples or ... These assays suffer from a number of limitations: , ... not as commonly available for novel sample matrices such as saliva as they are for ... be relatively costly due to the high volume of reagents used. , ...
Cached Biology Technology:A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 2A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 3A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 4A simple method to sequence from bacterial colonies using [a-33P] radiolabeled ddNTPs and Thermo Sequenase 2A simple method to sequence from bacterial colonies using [a-33P] radiolabeled ddNTPs and Thermo Sequenase 3Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 2Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 3Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 4
(Date:7/10/2014)... known as heme enzymes, due to the presence of ... centre of the heme cofactor is an iron (Fe) ... is in an intermediate state called Compound I. The ... this oxidation involves just an oxygen atom (O), or ... implications for understanding oxidative processes within living cells, which ...
(Date:7/10/2014)... HOUSTON (July 10, 2014) New research from ... (UTHealth) shows that It,s Your GameKeep it Real (IYG), ... and promote healthy dating relationships, can significantly reduce dating ... Centers for Disease Control and Prevention, 10 percent of ... and other studies suggest that more than 20 percent ...
(Date:7/10/2014)... Spanish National Cancer Research Centre (CNIO) Macromolecular Crystallography ... a protein called BuD to DNA in order ... Montoya, the researcher who led the study, says ... edit the instructions contained in the genome to ... The study is published in the journal ...
Breaking Biology News(10 mins):Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3It's Your Game ... Keep It Real reduces dating violence among minority youth 2CNIO scientists develop technology to redirect proteins towards specific areas of the genome 2
... Varanus komodoensis ) are known to bite prey and release ... the victims are reported to go into shock before the ... prey are killed by pathogenic bacteria in the dragons, mouths ... of Proceedings of the National Academy of Sciences ...
... active site found in a naturally occurring enzyme, chemists at ... like nature,s most pervasive hydrogen processor. , The researchers describe ... Journal of the American Chemical Society , and posted ... puzzled by nature,s ability to use cheap and plentiful building ...
... million cases of malaria are diagnosed each year mostly ... treat malaria do exist, the demand for new treatments ... have developed a resistance to existing medications. Now, ... have discovered one way to stop malaria parasite growth, ...
Cached Biology News:Komodo even more deadly than thought: Research 2New lead on malaria treatment 2
HyPro 20 system for slide hybridization. 20 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
Request Info...
Request Info...
Biology Products: